Clinical Trial Update: Title: Safety and Feasibility of Individualized Low Amplitude Seizure Therapy (iLAST) [Phase 1]

View source ↗

Summary

A Phase 1 safety and feasibility study of iLAST, an individualized low amplitude seizure therapy, for unipolar depression, has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Unipolar Depression

Drugs mentioned

• iLAST

Snippet

Sponsor: National Institute of Mental Health (NIMH) | Conditions: Unipolar Depression | Phase 1 | Status: WITHDRAWN